Contrasting Biodesix (NASDAQ:BDSX) and Pheton (NASDAQ:PTHL)

Biodesix (NASDAQ:BDSX) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Biodesix and Pheton, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1	0	2	0	2.33
Pheton	1	0	0	0	1.00

Biodesix currently has a consensus target price of $22.00, suggesting a potential upside of 46.08%. Given Biodesix’s stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Pheton.

Earnings & Valuation

This table compares Biodesix and Pheton”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50 million	1.76	-$35.26 million	($4.06)	-3.71
Pheton	$305,215.00	7.33	-$660,000.00	N/A	N/A

Pheton has lower revenue, but higher earnings than Biodesix.

Risk & Volatility

Biodesix has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the S&P 500.

Insider and Institutional Ownership

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Biodesix and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Pheton	N/A	N/A	N/A

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.